IP Library › Granted Patent US 12,648,928
Granted Patent B2
US 12,648,928 · App. 17/905,133 · Granted Jun 9, 2026

Intervention strategy for prevention or treatment of diabetes mellitus, autoimmune disease, inflammatory disease or cardiovascular disease

Inventors: Max Nieuwdorp (Amsterdam, NL); Willem Meindert De Vos (Amsterdam, NL)
Assignees: ACADEMISCH MEDISCH CENTRUM; WAGENINGEN UNIVERSITEIT
A61K31/405A61K9/4833A61K35/745A61K35/747A61P3/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,648,928
App. No.
17/905,133
Granted
Jun 9, 2026
Kind
B2
Abstract

An intervention strategy in the prevention or treatment of a subject having an inflammation-related disease such as Diabetes mellitus, autoimmune disease, inflammatory disease or cardiovascular disease. The intervention strategy preferably relates to administration of a chloro-, fluoro-, or bromo-substituted tryptophan, preferably 6-bromotryptophan, and/or a mono- or di-fatty acid substituted glycerol phosphocholine (GPC), preferably chosen from the group consisting of 1-myristoyl-2-arachidonoyl-glycero-phosphocholine (MA-GPC) and 1-arachidonoyl-glycero-phosphocholine (A-GPC), or any derivative or functional equivalent of these. Alternatively, the intervention relates to administration of a Desulfovibrio species, wherein the Desulfovibrio species is preferably chosen from the group consisting of Desulfovibrio piger, Desulfovibrio fairfieldensis, Desulfovibrio desulfuricans, desulfovibrio indonensis, Desulfovibrio alaskensis, Desulfovibrio vulgaris, Desulfovibrio vietnamensis and Desulfovibrio gigas.

Claims (4)

1 . A method of treating a subject for diabetes mellitus, the method comprising:

administering to the subject an amount of 6-bromotryptophan to treat the diabetes mellitus, wherein the 6-bromotryptophan is not comprised in fecal matter.

2 . The method according to claim 1 , wherein the subject has an elevated inflammatory immune profile, wherein the elevated inflammatory immune profile comprises increased levels of TNFα, IFNβ, IFNγ, or a combination thereof.

3 . The method according to claim 2 , wherein administration of the 6-bromotryptophan reduces secretion of one or more pro-inflammatory cytokines selected from TNFα, IFNβ, and IFNγ.

Assignments (2)
CHANGE OF NAME Recorded Sep 11, 2024
From: ACADEMISCH MEDISCH CENTRUM
To: STICHTING AMSTERDAM UMC
Reel/Frame 068942/0762 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2022
From: NIEUWDORP, MAX; DE VOS, WILLEM MEINDERT
To: ACADEMISCH MEDISCH CENTRUM; WAGENINGEN UNLVERSITEIT
Reel/Frame 060916/0933 →
Priority Claims (3)
NL 2025020 · Feb 28, 2020 · national
NL 2025021 · Feb 28, 2020 · national
NL 2025022 · Feb 28, 2020 · national
Continuity (1)
Related Publication 20230181531A1 · Jun 15, 2023
References Cited (39)
US 7670619B2 · Mihaylov · 2010 [cited by examiner]
US 20030225035A1 · Harats et al. · 2003 [cited by applicant]
CN 108785322A · 2018 [cited by applicant]
WO 2010083368A2 · 2010 [cited by applicant]
WO 2017072278A1 · 2017 [cited by applicant]
WO 2019168401A1 · 2019 [cited by applicant]
Tin et al. (J Am Soc Nephrol 29: 1939-1947, 2018). [cited by examiner]
Roager et al. (Nature Comm., (2018) 9:3294, 10 pages). [cited by examiner]
Burrello et al. (Cells 2019, 8, 517, 18 pages). [cited by examiner]
Guo et al. (BioMed Research International, 2013, 581631, 9 pages, 2013). [cited by examiner]
Jimenez (“Bromotryptophan and its Analogs in Peptides from Marine Animals”, Protein & Peptide Letters, vol. 26, Issue 4, 2019, pp. 251-260). [cited by examiner]
Peters (Biochemical Pharmacology, vol. 20 (1971), pp. 1413-1420). [cited by examiner]
International Search Report for International Application No. PCT/EP2021/054924, mailed Jul. 12, 2021, 7 pages. [cited by applicant]
International Written Opinion for International Application No. PCT/EP2021/054924, mailed Jul. 12, 2021, 12 pages. [cited by applicant]
Search Report and Written Opinion for the Netherlands Application No. NL 2025020, mailed Oct. 14, 2020, 8 pages. [cited by applicant]
Search Report and Written Opinion for the Netherlands Application No. NL 2025021, mailed Oct. 16, 2020, 10 pages. [cited by applicant]
Search Report and Written Opinion for the Netherlands Application No. NL 2025022, mailed Oct. 14, 2020, 9 pages. [cited by applicant]
Southam, et al. “Structural requirements of the competitive binding site of recombinant human indoleamine 2,3-dioxygenase” Medicinal Chemistry Research, vol. 6, Issue 5, Jan. 1, 1996, pp. 343-352 (Abstract Only). [cited by applicant]
Stefanaki et al. “Examining the gut bacteriome, virome, and mycobiome in glucose metabolism disorders: Are we on the right track?” Metabolism Clinical and Experimental, Issue 73 (May 2017) pp. 52-66. [cited by applicant]
Yamamoto et al. “Effects of Various Phytochemicals on Indoleamine 2,3-Dioxygenase 1 Activity: Galanal Is a Novel, Competitive Inhibitor of the Enzyme” PLOS ONE, vol. 9, Issue 2 (Feb. 2014) 8 pages. [cited by applicant]
Chinese First Office Action for Chinese Application No. 202180014499.X, dated Mar. 8, 2024, 10 pages with English translation. [cited by applicant]
Pubill-Ulldemolins et al. “Heck Diversification of Indole-Based Substrates under Aqueous Conditions: From Indoles to Unprotected Halo-tryptophans and Halo-tryptophans in Natural Product Derivatives” Chem. Eur. J. 2019, … [cited by applicant]
De Vos “Fame and future of faecal transplantations—developing next-generation therapies with synthetic microbiomes” Microb Biotechnol . Jul. 2013;6(4):316-25. doi: 10.1111/1751-7915.12047. Epub Apr. 10, 2013. [cited by applicant]
Ganju et al “Microbial community profiling shows dysbiosis in the lesional skin of Vitiligo subjects” Sci Rep 6, 18761 (Jan. 2016). [cited by applicant]
Henikoff et al “Amino acid substitution matrices from protein blocks” Proc Natl Acad Sci USA, Nov. 15, 1992;89(22):10915-9. [cited by applicant]
Japanese Notice of Reasons for Refusal for Japanese Application No. 2022-552221, dated Feb. 4, 2025, 13 pages with English translation. [cited by applicant]
Kolho et al. “Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation” Am J Gastroenterol. Jun. 2015;110(6):921-30. doi: 10.1038/ajg.2015.149. Epub May 19, 2015. [cited by applicant]
Korpela et al “Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children.” Nature communications vol. 7 10410. Jan. 26, 2016, doi:10.1038/ncomms10410. [cited by applicant]
Marazuela et al. “Regulatory T cells in human autoimmune thyroid disease”, J. Clin. Endocrinol. Metab. Sep. 2006; 91(9):3639-46 (Epub Jun. 27, 2006). [cited by applicant]
Rajilic-Stojanovic et al. “The first 1000 cultured species of the human gastrointestinal microbiota” FEMS Microbiology Reviews, vol. 38, Issue 5, Sep. 2014, pp. 996-1047,. [cited by applicant]
Saito et al. “4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-y-stimulated monocytes (THP-i cells)” Biochem. J. (1993) 291, 11-14 (Printed in Great Bri… [cited by applicant]
Tin et al. “Serum 6-Bromotryptophan Levels Identified as a Risk Factor for CKD Progression” J Am Soc Nephrol. May 18, 2018;29(7):1939-1947. [cited by applicant]
Verdu et al. “Common ground: shared risk factors for type 1 diabetes and celiac disease” Nature Immunology, vol. 19 (Jul. 2018) pp. 685-695. [cited by applicant]
Chen et al. “Isolation of [cited by applicant]
Cheng et al. “A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triplenegative breast cancer” JCI Insight. 2018;3(22):e120638 (Nov. 15, 2018). [cited by applicant]
Chou et al. “Impact of intracellular innate immune receptors on immunometabolism” Springer Nature, Cellular & Molecular Immunology (2022) 19:337-351 (Oct. 25, 2021). [cited by applicant]
Serna-Cock et al. “Probiotic encapsulation” African Journal of Microbiology Research, vol. 7(40), pp. 4743-4753, Oct. 4, 2013. [cited by applicant]
Koh et al. “Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1” Cell 175, 947-961 (Nov. 1, 2018). [cited by applicant]
Lachin et al. “Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Type 1 Diabetes” Plos One, vol. 6, Issue 11, e26471(Nov. 2011). [cited by applicant]